Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853241 | 1.00 | KDM4E (0.37) | KDM4EKMT2ANPSR1DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL28563629 | 0.98 | KDM4E (0.36) | KDM4EKMT2ANPSR1DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL28563631 | 0.98 | KDM4E (0.36) | KDM4EKMT2ANPSR1DPP9DPP7 | |
| SCHEMBL21553840 | 0.88 | KDM4E (0.44) | KDM4EKMT2ANPSR1DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL7343047 | 0.86 | KDM4E (0.42) | KDM4EKMT2ANPSR1DPP9DPP7 | |
| SCHEMBL34473335 | 0.83 | — | — | |
| Methane SCHEMBL27653701 | 0.78 | DPP9 (0.30) | KDM4EKMT2ADPP9DPP7 | |
| SCHEMBL20669232 | 0.77 | KDM4E (0.39) | KDM4EKMT2ANPSR1DPP9DPP7 | |
| SCHEMBL231396 | 0.75 | — | — | |
| SCHEMBL29956680 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-7348434-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | BIGOT ANTONY | 2008-03-25 | — | — | US | disclosed |
| US-20050032800-A1 | 4-Substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S. A. (FR) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | KDM4E 2153/4885KMT2A 2173/4885NPSR1 3406/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | KDM4E 2153/4885KMT2A 2173/4885NPSR1 3406/4885 |
| US-20050032800-A1 | 4-Substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | CBR3, HRH2, HRH4 | KDM4E 3474/4885KMT2A 3546/4885NPSR1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.